F Averhoff1, F Mahoney, P Coleman, G Schatz, E Hurwitz, H Margolis. 1. Hepatitis Branch World Health Organization Collaborating Center for Research and Reference in Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333.
Abstract
OBJECTIVE: To assess risk factors for decreased immunogenicity among adults vaccinated with hepatitis Bvaccine and to determine the importance of differences in immunogenicity between vaccines among health care workers (HCWs). DESIGN: Randomized clinical trial and decision analysis. PARTICIPANTS: HCSw. MAIN OUTCOME MEASURES: Development of seroprotective levels of antibody to hepatitis B surface antigen (anti-HBs) and the number of expected chronic hepatitis B virus (HBV) infections associated with lack of protection. RESULTS: Overall, 88% of HCWs developed seroprotection. Risk factors associated with failure to develop seroprotection included increasing age, obesity, smoking and male gender (P < .05). Presence of a chronic disease was associated with lack of seroprotection only among persons > or = 40 years of age (P < .05). The two vaccines studied differed in their overall seroprotection rates (90% vs. 86%; P < .05), however, this difference was restricted to persons > or = 40 years of age (87% vs. 81%; P < .01). Among HCWs > or = 40 years of age, the decision analysis found 44 (0.34/100,000 person-years) excess chronic HBV infections over the working life of the cohort associated with use of the less immunogenic vaccine compared to the other. CONCLUSIONS: He patitis B vaccines are highly immunogenic, but have decreased immunogenicity associated with increasing age, obesity, smoking, and male gender; and among older adults, the presence of a chronic disease. One of the two available vaccines is more immunogenic among older adults; however, this finding has little clinical or public health importance. Hepatitis B vaccines should be administered to persons at occupational risk for HBV infection early in their career, preferably while they are still in their training.
RCT Entities:
OBJECTIVE: To assess risk factors for decreased immunogenicity among adults vaccinated with hepatitis B vaccine and to determine the importance of differences in immunogenicity between vaccines among health care workers (HCWs). DESIGN: Randomized clinical trial and decision analysis. PARTICIPANTS: HCSw. MAIN OUTCOME MEASURES: Development of seroprotective levels of antibody to hepatitis B surface antigen (anti-HBs) and the number of expected chronic hepatitis B virus (HBV) infections associated with lack of protection. RESULTS: Overall, 88% of HCWs developed seroprotection. Risk factors associated with failure to develop seroprotection included increasing age, obesity, smoking and male gender (P < .05). Presence of a chronic disease was associated with lack of seroprotection only among persons > or = 40 years of age (P < .05). The two vaccines studied differed in their overall seroprotection rates (90% vs. 86%; P < .05), however, this difference was restricted to persons > or = 40 years of age (87% vs. 81%; P < .01). Among HCWs > or = 40 years of age, the decision analysis found 44 (0.34/100,000 person-years) excess chronic HBV infections over the working life of the cohort associated with use of the less immunogenic vaccine compared to the other. CONCLUSIONS: He patitis B vaccines are highly immunogenic, but have decreased immunogenicity associated with increasing age, obesity, smoking, and male gender; and among older adults, the presence of a chronic disease. One of the two available vaccines is more immunogenic among older adults; however, this finding has little clinical or public health importance. Hepatitis B vaccines should be administered to persons at occupational risk for HBV infection early in their career, preferably while they are still in their training.
Authors: Rania A Tohme; Debo Awosika-Olumo; Carrie Nielsen; Salma Khuwaja; Jennifer Scott; Jian Xing; Jan Drobeniuc; Dale J Hu; Cynthia Turner; Toni Wafeeg; Umid Sharapov; Philip R Spradling Journal: Vaccine Date: 2011-10-18 Impact factor: 3.641
Authors: Giovanna Vitaliti; Andrea Domenico Praticò; Carla Cimino; Giovanna Di Dio; Elena Lionetti; Mario La Rosa; Salvatore Leonardi Journal: World J Gastroenterol Date: 2013-02-14 Impact factor: 5.742
Authors: Aric A Prather; Martica Hall; Jacqueline M Fury; Diana C Ross; Matthew F Muldoon; Sheldon Cohen; Anna L Marsland Journal: Sleep Date: 2012-08-01 Impact factor: 5.849
Authors: Erik Seth Kramer; Charlotte Hofmann; Paula G Smith; Mitchell L Shiffman; Richard K Sterling Journal: Dig Dis Sci Date: 2009-06-11 Impact factor: 3.199
Authors: Salvatore Leonardi; Andrea Domenico Praticò; Elena Lionetti; Massimo Spina; Giovanna Vitaliti; Mario La Rosa Journal: World J Gastroenterol Date: 2012-10-28 Impact factor: 5.742